secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2025-07-14T23:59:59+00:00
Accession:  0000950170-25-095628
Event type: debt
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen reduces minimum cash covenant to $18.75M in third amendment to Morgan Stanley financing
--------------------------------------------------------------------------------

- Third Amendment to Financing Agreement dated July 14, 2025 lowers required U.S. qualified cash from $22.5M to $18.75M.
- Amendment with lenders managed by Morgan Stanley Tactical Value and agent Wilmington Trust.
- Effective July 14, 2025; no other changes to Financing Agreement terms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017025095628/0000950170-25-095628-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017025095628/fgen-20250714.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-095628

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer